ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bone density"

  • Abstract Number: 2143 • ACR Convergence 2024

    Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population

    Marina soledad Moreno Garcia1, Roxana González Mazario2, yedra uson Rodriguez3, Erardo meriño Ibarra4, Emilio Giner5, Juan Carlos Cobeta García6, Marilia Arce Benavente7, maria Dolores Fábregas canales8, Julia Ullier Bellmunt3, Giuliano Boselli3, pilar martinez Valles7, Jorge Juan Fragío Gil9, carlos Vazquez Galeano7 and Ana Turrion Nieves10, 1hospital Miguel Servet . Zaragoza, Zaragoza, Aragon, Spain, 2Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, 3hospital miguel servet, zaragoza, Aragon, Spain, 4Hospital San Jorge Huesca, zaragoza, 5Hospital Royo Villanova, Teruel, Spain, 6Hospital Ernest Lluch, zaragoza, 7hospital miguel servet, Zaragoza, 8Hospital de Barbastro, Huesca, Spain, 9Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, 10Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain

    Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…
  • Abstract Number: 1066 • ACR Convergence 2024

    Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics

    Krista Topalsky1, Lee Arphai2, Mary Ellen Amos2, Amanda Mertz2, Christopher Blum3, Timothy Godbey2, Lori Leonard2, Maya Mattar4, Elizabeth Cable2 and Robert Wenzell2, 1University Hospitals/ Case Western Reserve University, Shaker Heights, OH, 2Cleveland VA Medical Center, Cleveland, OH, 3Cleveland VA Medical Center, Cleveland, 4Louis Stokes VA medical Center, Mayfield Heights, OH

    Background/Purpose: Osteoporosis is a major public health concern in the United States, leading to significant morbidity, mortality, and increased economic burden. Fractures are projected to…
  • Abstract Number: 2226 • ACR Convergence 2024

    Site-specific Differences in the Association of Non-vertebral Major Osteoporotic Fractures and Rheumatoid Arthritis

    John Chen1, Malini Chandra2, Laura Carbone3, John Schousboe4, Elisha Garcia2 and Joan Lo2, 1Kaiser Permanente Oakland Medical Center, Oakland, CA, 2Kaiser Permanente, Oakland, CA, 3Augusta University, Augusta, GA, 4University of Minnesota, Minneapolis, MN

    Background/Purpose: Rheumatoid arthritis (RA) and osteoporosis are both chronic, potentially debilitating conditions that frequently co-occur, affecting millions of people annually. Among those with osteoporosis, RA…
  • Abstract Number: 1084 • ACR Convergence 2024

    Osteoporosis and Osteopenia Diagnosed by Dual-Energy X-Ray Absorptiometry Are Not Increased in Patients with Gout

    Karla Miller1, grant Cannon1, Kyle Register2, Nadia Grant2 and Naomi Schlesinger2, 1University of Utah and Salt Lake City VA, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    Background/Purpose: Controversy exists surrounding the association of gout with osteoporosis diagnosis or incident fragility fractures.  Dual-Energy X-Ray Absorptiometry (DXA) scan is the gold standard for…
  • Abstract Number: 2563 • ACR Convergence 2024

    Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial

    Jean-Yves Reginster1, Stuart L. Silverman2, Edward Czerwinski3, Przemyslaw Borowy4, Tomasz Budlewski5, Joanna Kwiatek6, Svitlana Postol7, Airi Põder8, Jerzy Supronik9, SungHyun Kim10, JeeHye Suh10, GoEun Yang10, NooRi Han10, NaHyun Kim10 and SeoHee Bae10, 1Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, 2OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, 3Krakow Medical Centre, Kraków, Poland, 4Krakowskie Centrum Medyczne, Krakow, Poland, 5Department of Rheumatology, Medical University of Lodz, Lodz, Poland, 6Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, 7Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, 8Clinical Research Centre Ltd, Tartu, Estonia, 9Osteo-Medic s.c., Białystok, Poland, 10Celltrion, Inc., Incheon, Republic of Korea

    Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…
  • Abstract Number: 1616 • ACR Convergence 2024

    Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis

    Gaston Ariel Ghio1, Marta Domínguez-Álvaro2, Ricardo Blanco-Alonso3, Santos Castañeda4, Iñigo Hernández-Rodríguez5, Elisa Fernández-Fernández:6, Maite Silva-Diaz7, Joaquin María Belzunegui:8, Clara Moriano9, Julio Sánchez-Martín10, Javier Narvaez-García11, Eva Galindez12, Anne Riveros Frutos13, Francisco Ortiz Sanjuán14, Tarek Carlos Salman Monte:15, Margarida Vasques Rocha:16, Carlota L Iñiguez:17, Alicia García Dorta18, Clara Molina Almela19 and María Alcalde Villar:20, and ARTESER Project Collaborative Group, 1Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, 2Sociedad Española de Reumatología, Madrid, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 4Hospital Universitario de la Princesa, Madrid, Spain, 5Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 6La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 7Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 8H de Donostia, Donostia-San Sebasti, Spain, 9Hospital León, LEON, Spain, 10Hospital Universitario 12 de Octubre, Madrid, Spain, 11Hospital Universitario de Bellvitge, Barcelona, Spain, 12Hospital Universitario de Cabueñes, Bilbao, Spain, 13Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 14Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, 15Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 16Hospital Universitario Araba, Vitoria, Spain, 17Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, 18Rheumatologist, La Laguna, Spain, 19Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 20Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain

    Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
  • Abstract Number: 2114 • ACR Convergence 2024

    CT and DXA Bone Fragility Evaluation After Bariatric Surgery

    Marine FAUNY1, Marion Halin2, Edem Allado2, Laurent Brunaud2, Claire Nomine Criqui2, Eliane Albuisson2, Isabelle Chary-Valckenaere3, Damien Loeuille4 and Didier Quilliot2, 1CH TOUL, Toul, Lorraine, France, 2Nancy University Hospital, Vandoeuvre, Lorraine, France, 3Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, 4Phd, Nancy Vandoeuvre, Lorraine, France

    Background/Purpose: Bariatric surgery could impact bone metabolism and induce significant changes, leading to increased bone resorption and an increased risk of fractures.The primary objective was…
  • Abstract Number: 1996 • ACR Convergence 2023

    Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics

    Karla Miller1, Melissa Steffen2, Kimberly McCoy2, Michelle Mengeling2, Heather Davila2, Shylo Wardyn2 and Samantha Solimeo2, 1University of Utah School of Medicine, Salt Lake City, UT, 2Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA

    Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
  • Abstract Number: 1997 • ACR Convergence 2023

    A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis

    Richard Eastell1, Bente Langdahl2, Yoon-Sok Chung3, Rafal Plebanski4, Edward Czerwinski5, Eva Dokoupilova6, Jerzy Supronik7, Jan Rosa8, Anna Rowińska-Osuch9, Ki-Hyun Baek10, Audrone Urboniene11, Sohui Ahn12, Younghee Rho12 and Jisuk Ban12, 1University of Sheffield, Sheffield, United Kingdom, 2Aarhus University Hospital, Aarhus, Denmark, 3Ajou University Hospital, Suwon, South Korea, 4Klinika Zdrowej Kosci, Łódź, Poland, 5Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, 6Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, 7OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, 8Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, 9ETG Warszawa, Warszawa, Poland, 10Yeouido ST. Mary's Hospital, Seoul, South Korea, 11JSC Saules seimos medicinos centras, Kaunas, Lithuania, 12Samsung Bioepis, Incheon, South Korea

    Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
  • Abstract Number: 2000 • ACR Convergence 2023

    Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study

    Mai Kawazoe1, Kaichi Kaneko2, Shotaro Masuoka3, Soichi yamada3, Zento Yamada3, Sei Muraoka3, Karin Furukawa1, Hiroshi Sato3, Eri Watanabe3, Keiko Koshiba3, Izumi Irita3, Miwa Kanaji3 and Toshihiro Nanki1, 1Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, 2Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, 3Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including rheumatic diseases. Although glucocorticoids improve the outcome for these diseases, various side effects…
  • Abstract Number: 2003 • ACR Convergence 2023

    Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis

    Ruban Dhaliwal1, John Boxberger2, Yamei Wang2, Bruce Mitlak2, Ludovic Humbert3 and Neil Binkley4, 1Massachusetts General Hospital, Boston, MA, 2Radius Health, Inc., Boston, MA, 33D-Shaper Medical, Barcelona, Spain, 4University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI

    Background/Purpose: Abaloparatide (ABL) increases BMD in men with osteoporosis. In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) trial, DXA-measured BMD change with…
  • Abstract Number: 2007 • ACR Convergence 2023

    Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study

    Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY

    Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
  • Abstract Number: 2011 • ACR Convergence 2023

    Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis

    Nicholas Rossi1, Aamir Saeed2, Aqib Khan3, Hamzah Amin2, Ummaz Nadeem2, Zain Sultan3 and Marwan Bukhari2, 1University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, 2Lancaster University, Lancaster, United Kingdom, 3University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom

    Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…
  • Abstract Number: 2123 • ACR Convergence 2023

    Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?

    Jia-Feng Chen1, Tien-Tsai Cheng2 and Hong-Yo Kang3, 1Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 2Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan, 3Graduate Institute of Clinical Medical Sciences, Chang Gung University, College of Medicine, Kaohsiung, Taiwan

    Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…
  • Abstract Number: 2318 • ACR Convergence 2023

    The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study

    Vrati Mehra1, Daniela Dominguez2, Nicholas Gold2, Andrea Knight2, Deborah Levy2, Fangming Liao2, Eleanor Pullenayegum2, Amer Shammas2, etienne Sochett2, Reza vali2, Declan Webber3, Earl Silverman4 and Linda Hiraki2, 1The Hospital for Sick Children & University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3University of Toronto, Mississauga, ON, Canada, 4Silverman, Toronto, ON, Canada

    Background/Purpose: Childhood-onset systemic lupus erythematosus patients < 18 years (cSLE) are at risk for reduced bone mineral density (BMD) due to disease activity and chronic…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology